autologous TBX-4000-treated peripheral blood mononuclear cells TBX-3400

{
  "id": "MLC-T-ONC-011769",
  "term": "autologous TBX-4000-treated peripheral blood mononuclear cells TBX-3400",
  "field": "Oncology and biomedicine",
  "definition": "An autologous cell preparation in which the autologous peripheral blood mononuclear cells (PBMCs) are treated ex vivo with TBX-4000, a recombinant TAT-MYC fusion protein, with potential antineoplastic and immunomodulating activities. Upon reintroduction of the TBX-3400 cells into the patient, the generated T cells may activate the immune system and exert a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. The TBX-4000 recombinant fusion protein consists of the N-terminal 9 amino acid segment of the HIV TAT protein transduction domain (PTD) fused to the MYC protein. TBX-4000 TAT-MYC rapidly localizes to the nucleus and transiently provides signals to drive proliferation and survival of T cells.",
  "synonyms": [
    "autologous TBX-4000-treated human PBMCs",
    "TBX-3400 cells",
    "autologous PBMCs TBX-3400"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/autologous-tbx-4000-treated-peripheral-blood-mononuclear-cells-tbx-3400/"
}